Associated Papers
Changes in EGFR activity following CRISPR/Cas9-editing of the EGF binding domain.
Popović J et al.
Scientific Reports, 2026
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Silva-Oliveira RJ et al.
Cellular Oncology (dordrecht, Netherlands), 2016
Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.
Liu G et al.
Oncogene, 2011
Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes.
Bheda A et al.
Oncogene, 2008
Select a paper to view details